Auricular point stimulation with dexamethasone vs standard antiemetics for chemo-induced nausea in pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 trial compares two antiemetic strategies for patients with pancreatic cancer receiving gemcitabine and nab-paclitaxel. One arm uses auricular point stimulation plus dexamethasone, while the control arm uses a standard pharmacologic antiemetic regimen. The study also looks at appetite, gastrointestinal function, and quality of life to see if the traditional Chinese medicine approach can provide non-inferior control of symptoms with potential QoL benefits. Eligible participants are adults with pancreatic cancer who are scheduled for this chemotherapy, with adequate organ function and performance status. The trial is conducted at a major Chinese medical center and is sponsored by the Second Affiliated Hospital, Zhejiang University School of Medicine.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients must meet the following inclusion criteria for the study: \* Age ≥ 18 years and ≤ 85 years; \* Patients with pancreatic cancer after radical resection or with advanced pancreatic cancer, who require further chemotherapy with the gemcitabine plus paclitaxel albumin-bound regimen; \* ECOG performance status score of 0-2; \* Normal hematological function (platelet count \> 80×10⁹/L; white blood cell count \> 3×10⁹/L; neutrophil count \> 1.5×10⁹/L); \* Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), and transaminase ≤ 5 times the ULN; \* No ascites, no gastrointestinal obstruction, normal coagulation function, and serum albumin ≥ 30g/L; \* Child-Pugh classification of liver function is Grade A; \* Serum creatinine \< ULN, or calculated creatinine clearance rate \> 50ml/min.

Exclusion Criteria:

* Patients who meet any of the following criteria will be excluded from the study: \* Local inflammation or infection of the auricleBleeding tendency or coagulation disorders; \* Severe ascites; \* Gastrointestinal obstruction; \* Hypertensive crisis or hypertensive encephalopathy; \* Severe uncontrolled systemic complications such as infection or diabetes mellitus; \* Clinically severe cardiovascular diseases, including cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), hypertension that is not well-controlled despite appropriate medication, unstable angina pectoris, congestive heart failure (NYHA Class 2-4), and cardiac arrhythmias requiring drug treatment; \* A history of or physical examination findings indicating central nervous system diseases (e.g., primary brain tumor, epilepsy uncontrolled by standard treatment, any history of brain metastasis or stroke); \* Hypersensitivity to any drugs used in the study; \* Pregnant or lactating women; \* Presence of any other diseases, functional impairment caused by metastatic lesions, or suspicious disorders identified during physical examination, which suggest contraindications to the study drugs or place the patient at high risk of treatment-related complications; \* Inability or unwillingness to comply with the study protocol.

Where it's running

• Second Affiliated Hospital of Zhejiang University School of Medicine
  Hangzhou, China Recruiting

Study contacts

• Study coordinator: Juan Wang
• Email: wangjuan.happy@hotmail.com
• Phone: 8617816190946

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Auricular Point Stimulation With Dexamethasone vs Standard Anti-nausea Medications for Docetaxel‑Cyclophosphamide Therapy

  This study tests whether adding ear acupuncture-like stimulation to dexamethasone can match or be as effective as standard antiemetic drugs for preventing nausea and vomiting in people receiving the docetaxel–cyclophosphamide chemotherapy.

  Recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07716176

• Ear acupressure plus dexamethasone to prevent chemo nausea from docetaxel and cyclophosphamide

  This trial will test whether ear acupressure (auricular point stimulation) combined with dexamethasone can prevent or reduce nausea and vomiting in adults receiving docetaxel plus cyclophosphamide after breast cancer surgery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07537699

• Ear acupressure plus dexamethasone to prevent nausea and vomiting during gemcitabine and albumin‑bound paclitaxel treatment for pancreatic cancer

  This will see if ear acupressure with bean seeds plus an IV dose of dexamethasone can prevent nausea and vomiting in people with pancreatic cancer receiving gemcitabine combined with albumin‑bound paclitaxel.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07537660

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.